Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Healthy Alaskan.
Press releases published on June 13, 2025
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy
GlobeNewswire
·
June 13, 2025
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy PolTREG established Immuthera (https://immuthera.bio/) in Delaware to expand its presence in the U.S. market. A Pre-IND application was submitted to …
The Dental Medical Convergence Announces Featured Article and Podcast Interview on KevinMD Highlighting Dangers of Dental Infections
GlobeNewswire
·
June 13, 2025
Eustis, Florida , June 13, 2025 (GLOBE NEWSWIRE) -- The Dental Medical Convergence, a nonprofit dedicated to educating the public about the link between oral health and systemic disease, announced today that KevinMD—widely recognized as social media’s …
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
GlobeNewswire
·
June 13, 2025
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
13171229 B.C. Ltd. and Launchit Solutions Inc. Announce Execution of Business Combination Agreement and Launchit’s Concurrent Financing
GlobeNewswire
·
June 13, 2025
VANCOUVER, British Columbia, June 13, 2025 (GLOBE NEWSWIRE) -- 1317229 B.C. Ltd. (“131” or the “Company”) and Launchit Solutions Inc. (“Launchit”) are pleased to announce that the Company, Launchit and 1001240330 Ontario Inc. (“Subco”), a wholly-owned …
GT Biopharma Appoints New Member to its Board of Directors
GlobeNewswire
·
June 13, 2025
SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer …
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
GlobeNewswire
·
June 13, 2025
– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma – – Data supports ongoing Phase 2 …
InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke
GlobeNewswire
·
June 13, 2025
MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device …
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
GlobeNewswire
·
June 13, 2025
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for …
Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees
GlobeNewswire
·
June 13, 2025
TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that leading independent proxy …
Sienna Announces June Dividend
GlobeNewswire
·
June 13, 2025
MARKHAM, Ontario, June 13, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of June 2025, representing $0. …
Flow Cytometry Market Hits US$10.3B by 2032: Why Every Lab Needs a FACS Flow Cytometer?
GlobeNewswire
·
June 13, 2025
Delray Beach, FL, June 13, 2025 (GLOBE NEWSWIRE) -- Ever wondered how scientists peek inside our cells, analyzing their secrets to diagnose diseases or develop life-saving therapies? It's all thanks to flow cytometry, a dynamic field transforming …
Rose Hill Apothecary Executes First Major International Export Deal, Supplying Research-Grade Psilocybin to Brazil
GlobeNewswire
·
June 13, 2025
RUNAWAY BAY, Jamaica, June 13, 2025 (GLOBE NEWSWIRE) -- Rose Hill Apothecary (“The Company” or “Rose Hill”), a global leader in the research and intellectual property of premium psilocybin products, today announced the successful execution of its first …
Tiziana Life Sciences to Present at the Bio International Convention
GlobeNewswire
·
June 13, 2025
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
Safety Shot, Inc. and Yerbaé Brands Corp Majority Shareholders Approve Proposed Acquisition of Yerbaé Brands Corp.
GlobeNewswire
·
June 13, 2025
SCOTTSDALE, AZ, June 13, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”), a wellness and dietary supplement company, today announced that it a majority of its shareholders have voted by a majority to approve the …
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 13, 2025
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and …
Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025
GlobeNewswire
·
June 13, 2025
Showcased 7 presentations at ISSCR 2025, including a featured oral presentation on first-in-human gene therapy for heart failure, powered by their proprietary human mini-Heart technology. FDA-backed human-based screening platform recognized as an animal- …
Panavance Therapeutics Announces Promising Misetionamide (GP-2250) Phase 1 Clinical Trial Interim Findings in Pancreatic Cancer at BIO 2025
GlobeNewswire
·
June 13, 2025
Interim analysis shows misetionamide is very well tolerated in combination with gemcitabine; rates of confirmed response, stable disease, and progression-free survival compare favorably with gemcitabine monotherapy BERWYN, PA, June 13, 2025 (GLOBE NEWSWIRE …
Grace Therapeutics to Participate in the 2025 BIO International Conference
GlobeNewswire
·
June 13, 2025
PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed …
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
GlobeNewswire
·
June 13, 2025
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the sale of approximately …
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
GlobeNewswire
·
June 13, 2025
HANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that members of its executive leadership team will …